	US 12,329,803 B2
	Method of reducing or treating fibrosis by administering an interleukin-2/TGF-beta receptor fusion polypeptide
Claudia Ania Penafuerte Diaz, Montreal (CA)
Assigned to Cura Therapeutics Inc., Montreal (CA)
Filed by Cura Therapeutics, Inc., Montreal (CA)
Filed on Apr. 28, 2023, as Appl. No. 18/309,450.
Application 18/309,450 is a division of application No. 17/673,691, filed on Feb. 16, 2022, granted, now 11,672,844.
Claims priority of provisional application 63/150,450, filed on Feb. 17, 2021.
Prior Publication US 2023/0364186 A1, Nov. 16, 2023
Int. Cl. A61K 38/17 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/71 (2006.01)

CPC A61K 38/179 (2013.01) [A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/71 (2013.01); C07K 2319/30 (2013.01)]

23 Claims

1. A method of reducing or treating fibrosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a fusion polypeptide comprising:

an interleukin-2 (IL 2) polypeptide or a fragment thereof comprising an IL-2 receptor binding domain;

a first soluble TGFβ receptor II (sTβRII) polypeptide or a fragment thereof comprising a ligand binding domain;

and a second soluble TGFβ receptor II (sTβRII) polypeptide or a fragment thereof comprising a ligand binding domain,

thereby reducing or treating fibrosis in the subject.